A Comparative Study of the Efficacy of Detach(R) Versus Zinc Oxide to Control Post-Weaning Diarrhoea in Piglets

Sydney, Nov 21, 2017 AEST (ABN Newswire) - At the Australasian Pig Science Association (APSA) Conference in Melbourne this week, Dr Trish Holyoake & Dr Tracey Mynott presented a poster highlighting the comparable efficacy of a single dose of Anatara's (ASX:ANR) Detach(R) product to in-feed Zinc oxide (ZnO) in reducing diarrhoea and antibiotic treatments in post-weaning piglets. These results are significant given the push to remove ZnO from the food chain.


Anatara Lifesciences is currently applying for re-registration of Detach(R) as an alternative to antibiotics and Zinc Oxide (ZnO) to aid in the control of pre- and post-weaning diarrhoea in piglets. Bromelain, the active in Detach(R) reduces diarrhoea through its anti-attachment and anti-secretory effect (see Notes 1, 2 below) on the intestine, and is therefore unlikely to contribute to antimicrobial resistance. This study was designed to compare the efficacy of a single 4mL Detach(R) drench at weaning (18-28 days of age) to ZnO (2,500 ppm in feed) as an aid in the control of post-weaning diarrhoea in piglets.


A single dose of Detach(R) at weaning was as effective as in-feed ZnO in reducing diarrhoea and antibiotic treatments in piglets post-weaning compared to untreated piglets.


Literature Cited:

1 Chandler DS, Mynott TL (1998) Gut 43, 196-202;

2 Mynott TL, Guandalini S, Raimondi F, Fasano A (1997) Gastroenterology 113, 175-184

To view tables and figures, please visit:

About Anatara Lifesciences Ltd

Anatara Lifesciences ASX ANRAnatara Lifesciences (ASX:ANR) is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach(R) is a natural plant based product that will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called “super bugs” that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies. Please see http://www.anataralifesciences.com for further background.



Investor inquiries:
Dr Mel Bridges
Chairman & CEO
Anatara Lifesciences
Phone: +61-413-051-600
Email: mbridges@anataralifesciences.com

Media inquiries:
Jane Lowe
IR Department
Phone: +61-411-117-774
Email: jane.lowe@irdepartment.com.au

Related Companies

Anatara Lifesciences Ltd

ABN Newswire This Page Viewed:  (Last 7 Days: 61) (Last 30 Days: 168) (Since Published: 1144) 

Anatara Lifesciences Ltd NEWS: RECENT VISITS (3391)

Research Report

Social Media